Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03704688 · ClinicalTrials.gov registry record · Phase 1
Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT03704688: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03704688 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03704688, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety of the combination of ponatinib and trametinib as well as the most appropriate dosages of the combination.
Interventions
- DRUG Trametinib 0.5 mg
- DRUG Trametinib 1 MG
- DRUG Trametinib 1.5 MG
- DRUG Trametinib 2 mg
- DRUG Ponatinib 15 MG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2018-10-09 |
| Est. Completion | 2022-02-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03704688
The ClinicalTrials.gov registry entry for NCT03704688 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Trametinib 0.5 mg is the first listed.
NCT03704688 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03704688 about?
NCT03704688 is a clinical study titled "Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer". The purpose of this study is to evaluate the safety of the combination of ponatinib and trametinib as well as the most appropriate dosages of the combination.
What is the current status of trial NCT03704688?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2018-10-09. Estimated completion is 2022-02-04.
What interventions are being tested in trial NCT03704688?
The interventions under investigation include: Trametinib 0.5 mg (DRUG), Trametinib 1 MG (DRUG), Trametinib 1.5 MG (DRUG), Trametinib 2 mg (DRUG), Ponatinib 15 MG (DRUG).
Who is sponsoring clinical trial NCT03704688?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.